Telix Pharmaceuticals Submits Brain Cancer Imaging Agent TLX101-Px for Regulatory Approval

Telix Pharmaceuticals has resubmitted a new drug application (NDA) for its progressive glioma imaging agent, TLX101-Px, to the U.S. Food and Drug Administration (FDA). The company has also submitted a marketing authorization application to the European Medicines Agency (EMA) for the same product.

The NDA resubmission follows further data requested by the FDA, including additional statistical analysis and primary data set provided in the original submission. Due to significant unmet medical needs and the urgent nature of the trial, TLX101-Px has been granted Orphan Drug and Fast Track designations by the FDA.

The submission covers major European markets and forms part of a coordinated regulatory approach, with European and U.S. dossiers being prepared in parallel. The company seeks approval to market TLX101-Px across European Union member states, Iceland, Norway, and Liechtenstein.

TLX101-Px is designed as a PET imaging agent for glioma, the most common type of primary brain tumor. The application follows clinical studies that evaluated the safety and efficacy of TLX101-Px in imaging glioblastoma tumors. If approved, the imaging agent could help clinicians distinguish tumor progression or recurrence from treatment-related effects, an area where conventional MRI scans can often provide inconclusive results and delay treatment decisions.

Although similar imaging approaches are already used in Europe under limited hospital-based production, there is currently no widely available commercial product that provides consistent quality and access. The company is seeking a broad clinical label aligned with current practice guidelines.

Across Europe, around 67,500 brain and central nervous system tumors are diagnosed each year, with gliomas accounting for a significant share of malignant cases. Glioblastoma is known for its poor prognosis and limited treatment options, making advancements in diagnostic imaging critical for patient management.

TLX101-Px also has a strategic role beyond diagnosis, as it is being developed as a companion diagnostic and response-assessment tool for Telix's investigational glioblastoma therapy TLX101-Tx. That therapy is currently being evaluated in a Phase 3 clinical study in Europe, reflecting Telix's broader precision-medicine strategy of pairing imaging and treatment within the same molecular targeting framework.

If authorized, the product would be marketed in Europe under the proposed brand name Pixlumi, although final naming and launch timing remain subject to regulatory approval. The group chief medical officer stated that the resubmission is supported by an extensive and compelling data set, particularly so for an orphan indicator.